Several other research firms have also recently weighed in on HZNP. UBS Group cut shares of Horizon Therapeutics Public from a buy rating to a neutral rating and lowered their price objective for the company from $137.00 to $71.00 in a research report on Thursday, August 4th. Morgan Stanley lowered their price objective on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an overweight rating on the stock in a research report on Thursday, August 4th. Piper Sandler lowered their price objective on shares of Horizon Therapeutics Public from $90.00 to $88.00 and set an overweight rating on the stock in a research report on Tuesday, October 25th. HC Wainwright assumed coverage on shares of Horizon Therapeutics Public in a research report on Tuesday, November 1st. They set a neutral rating and a $74.00 price objective on the stock. Finally, SVB Leerink lifted their target price on shares of Horizon Therapeutics Public from $80.00 to $88.00 and gave the stock an outperform rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Horizon Therapeutics Public presently has a consensus rating of Moderate Buy and an average price target of $105.00.
Horizon Therapeutics Public Stock Performance
Horizon Therapeutics Public stock opened at $77.53 on Tuesday. The firm’s fifty day moving average price is $67.79 and its 200-day moving average price is $74.34. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.74 and a current ratio of 3.96. The stock has a market cap of $17.57 billion, a P/E ratio of 31.77, a price-to-earnings-growth ratio of 1.54 and a beta of 1.09. Horizon Therapeutics Public has a fifty-two week low of $57.84 and a fifty-two week high of $117.49.
Institutional Investors Weigh In On Horizon Therapeutics Public
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.
- Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.